Virology. Mutation rate and genotype variation of Ebola virus from Mali case sequences.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The occurrence of Ebola virus (EBOV) in West Africa during 2013-2015 is unprecedented. Early reports suggested that in this outbreak EBOV is mutating twice as fast as previously observed, which indicates the potential for changes in transmissibility and virulence and could render current molecular diagnostics and countermeasures ineffective. We have determined additional full-length sequences from two clusters of imported EBOV infections into Mali, and we show that the nucleotide substitution rate (9.6 × 10(-4) substitutions per site per year) is consistent with rates observed in Central African outbreaks. In addition, overall variation among all genotypes observed remains low. Thus, our data indicate that EBOV is not undergoing rapid evolution in humans during the current outbreak. This finding has important implications for outbreak response and public health decisions and should alleviate several previously raised concerns.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Science

Title: Science (New York, N.Y.)

ISSN (Electronic): 1095-9203

ISSN (Print): 0036-8075

Publication date (Electronic): Apr 3 2015

Volume: 348

Issue: 6230

Affiliations

[1 ] Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA.

[2 ] Bioinformatics and Computational Biosciences Branch, NIAID, NIH, Bethesda, MD 20892, USA.

[3 ] Center of Research and Training for HIV and Tuberculosis, University of Science, Technique and Technologies of Bamako, Mali.

[4 ] World Health Organization Office, Bamako, Mali.

[5 ] Centre des Operations d'Urgence, Centre pour le Développement des Vaccins (CVD-Mali), Centre National d'Appui à la lutte contre la Maladie, Ministère de la Sante et de l'Hygiène Publique, Bamako, Mali.

[6 ] World Health Organization Inter-Country Support Team, Ouagadougou, Burkina Faso.

[7 ] Rocky Mountain Veterinary Branch, Division of Intramural Research, NIAID, NIH, Hamilton, MT 59840, USA.

[8 ] Office of the Scientific Director, NIAID, NIH, Bethesda, MD 20895, USA.

[9 ] Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Hamilton, MT 59840, USA. feldmannh@niaid.nih.gov ssow@medicine.umaryland.edu.

[10 ] Centre des Operations d'Urgence, Centre pour le Développement des Vaccins (CVD-Mali), Centre National d'Appui à la lutte contre la Maladie, Ministère de la Sante et de l'Hygiène Publique, Bamako, Mali. feldmannh@niaid.nih.gov ssow@medicine.umaryland.edu.

Article

Publisher Item ID: science.aaa5646

DOI: 10.1126/science.aaa5646

PubMed ID: 25814067

SO-VID: bfc26d1b-d35c-45eb-bca3-fb9363f4c8c9

History

Data availability:

Comments

Comment on this article

scite_

Cited by 45

See all cited by